Investigating the role of a protein in aggressive kidney cancer and its treatment potential
Official title: The role of Angiopoietin-like 4 in clear cell renal cell carcinoma and its therapeutic potential
Funded at University of Florida · NIH-11047156 · Data updated 2026-11-12
This study is looking at how a protein called ANGPTL4 affects kidney cancer growth and whether blocking it can help make treatments work better for people with clear cell renal cell carcinoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $371,905 |
| NIH project number | 1R01CA288749-01A1 |
| Project ID | NIH-11047156 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who may not respond well to current therapies.
✕Less likely to help
Patients with other types of kidney cancer or those who have already responded well to existing treatments may not benefit from this research.
What this research studies
This research focuses on clear cell renal cell carcinoma (ccRCC), a common and aggressive type of kidney cancer. It aims to understand the role of Angiopoietin-like 4 (ANGPTL4), a protein that may influence tumor growth and blood vessel formation. The researchers will explore how blocking ANGPTL4 can reduce tumor growth and improve the effectiveness of existing cancer therapies. By identifying patient groups that may benefit from this approach, the study seeks to enhance treatment outcomes for ccRCC patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with clear cell renal cell carcinoma.
How similar studies have gone: Previous research has shown promising results in targeting angiogenesis in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Kolb, Ryan H — University of Florida
- Study coordinator: Kolb, Ryan H
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.